As filed with the Securities and Exchange Commission on August 11, 2022

Registration No. 333-            






Washington, D.C. 20549









UroGen Pharma Ltd.

(Exact name of registrant as specified in its charter)




State of Israel   98-1460746

(State or other jurisdiction of

incorporation or organization)


(I.R.S. Employer

Identification No.)


400 Alexander Park Drive, 4th Floor

Princeton, New Jersey

(Address of Principal Executive Offices)   (Zip Code)

2017 Equity Incentive Plan

(Full titles of the plans)

UroGen Pharma Ltd.

Jason Smith

General Counsel

400 Alexander Park Drive, 4th Floor

Princeton, New Jersey 08540

Telephone: +1 (646) 768-9780

(Name, address and telephone number, including area code, of agent for service)

Copies to:

Charles J. Bair

Asa M. Henin

Cooley LLP

4401 Eastgate Mall

San Diego, California 92121

+1 (858) 550-6000



Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐





This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective. The Registrant previously registered its Ordinary Shares for issuance under the Registrant’s 2017 Equity Incentive Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on June  27, 2017 (File No. 333-218992), February 9, 2018 (File No. 333-222955), October 12, 2018 (File No.  333-227812), August 10, 2020 (File No.  333-243750) and August 5, 2021 (File No. 333-258496). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.






4.1    Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Report on Form 6-K, furnished to the Securities and Exchange Commission on May 18, 2017).
5.1    Opinion of Erdinast Ben Nathan, Toledano & Co. With Hamburger Evron, Israeli counsel to the Registrant, as to the validity of the Registrant’s Ordinary Shares.
23.1    Consent of Independent Registered Public Accounting Firm.
23.2    Consent of Erdinast Ben Nathan, Toledano & Co. With Hamburger Evron. Reference is made to Exhibit 5.1.
24.1    Powers of Attorney. Reference is made to the signature page hereto.
99.1    UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 13, 2022).
107    Calculation of Filing Fee Table


Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, State of New Jersey, on August 11, 2022.



/s/ Elizabeth Barrett

  Elizabeth Barrett
  President and Chief Executive Officer


KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Elizabeth Barrett and Don Kim, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.







/s/ Elizabeth Barrett


President, Chief Executive Officer and

Member of the Board of Directors

(Principal Executive Officer)

  August 11, 2022

Elizabeth Barrett


/s/ Don Kim


Chief Financial Officer

(Principal Financial and Accounting Officer)

  August 11, 2022
Don Kim

/s/ Arie Belldegrun, M.D.

   Chairman of the Board of Directors   August 11, 2022
Arie Belldegrun, M.D.     

/s/ Cynthia M. Butitta

   Member of the Board of Directors   August 11, 2022
Cynthia M. Butitta     

/s/ Fred E. Cohen

   Member of the Board of Directors   August 11, 2022
Fred E. Cohen     

/s/ Stuart Holden

   Member of the Board of Directors   August 11, 2022
Stuart Holden     

/s/ Ran Nussbaum

   Member of the Board of Directors   August 11, 2022
Ran Nussbaum     

Exhibit 5.1



August 11, 2022


UroGen Pharma Ltd.

9 Ha’Ta’ssiya Street

Ra’anana 4365007


Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as Israeli counsel for UroGen Pharma Ltd., an Israeli company (the “Company”), in connection with the Registration Statement on Form S-8 (theRegistration Statement”) filed by the Company on the date hereof with the U.S. Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”). The Registration Statement relates to the registration of 400,000 of the Company’s ordinary shares, nominal value NIS 0.01 per share (the “Shares”), issuable under the UroGen Pharma Ltd. 2017 Equity Incentive Plan (the “Plan”).

In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the Registration Statement to which this opinion is attached as an exhibit; (ii) a copy of the articles of association of the Company, as currently in effect (the “Articles”); (iii) resolutions of the board of directors and the shareholders of the Company, which relate to the Registration Statement and the Plan; and (iv) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to these opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company. In addition, we have assumed that the Shares and any equity awards that provide for the acquisition thereof will be granted in accordance with the Plan and the Articles.



Based upon and subject to the foregoing, we are of the opinion that the issuance of the Shares pursuant to the Plan has been duly and validly authorized and that, upon the grant of any such Shares or awards, and the vesting, exercise and/or settlement, as the case may be, of any equity awards to acquire Shares, in each case pursuant to the Plan and the Articles, such Shares will be validly issued, fully paid and non-assessable.

Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of the SEC’s Regulation S-K under the Securities Act.

This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.


Very truly yours,
Erdinast, Ben Nathan, Toledano & Co. with Hamburger Evron

/s/ Yaron Sobol, Adv.

  Yaron Sobol, Adv.




Exhibit 23.1


We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of UroGen Pharma Ltd. of our report dated March 21, 2022 relating to the financial statements, which appears in UroGen Pharma Ltd.’s Annual Report on Form 10-K for the year ended December 31, 2021.

/s/ PricewaterhouseCoopers LLP

Florham Park, New Jersey

August 11, 2022


Exhibit 107


Form S-8

UroGen Pharma Ltd.

Table 1 – Newly Registered Securities


Security Type   Security
Class Title
Price Per
  Maximum Aggregate
Offering Price
  Fee Rate   Amount of
Equity   Ordinary Shares, par value NIS 0.01 per share to be issued pursuant to future awards under the UroGen Pharma Ltd. 2017 Equity Incentive Plan (the “Plan”)   457(c); 457(h)   400,000 shares(2)   $8.09(3)   $3,236,000.00(3)   0.0000927   $299.98
Total Offering Amounts   400,000 shares     $3,236,000.00     $299.98
Total Fee Offsets           $0.00
Net Fee Due                   $299.98



Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of UroGen Pharma Ltd.’s (the “Registrant”) Ordinary Shares (“Ordinary Shares”) that become issuable under the Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction.


Represents Ordinary Shares that were added to the shares authorized for issuance under the Plan. On March 7, 2022, the Registrant’s Board of Directors approved an amendment to the Plan to increase the number of Ordinary Shares authorized for issuance thereunder by 400,000 Ordinary Shares, for new total of 4,750,167 Ordinary Shares, which amendment was approved by the Registrant’s shareholders on June 8, 2022.


This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee, and is based on the average of the high and low sale prices per Ordinary Share as reported by The Nasdaq Global Market on August 4, 2022.